Argonaut Therapeutics is assembling an international team of scientists and clinicians that strive to combat cancer through developing innovative and proprietary therapies. Argonaut Therapeutics has pioneered the development of inhibitors of protein arginine methyl-transferase (PRMT).
Arginine methylation is a level of protein control which plays an important role in cellular processes, such as epigenetic control, RNA processing and protein translation, which contribute to cancer growth and division. Our scientists have found that arginine methylation is a key mechanism that is responsible for keeping cancer cells in a continuous state of growth. By targeting the vital PRMT enzymes, Argonaut is pioneering an approach to halt cancer cell growth by reinstating natural cell suicide mechanisms.